HIV-1 Infection Clinical Trial
Official title:
An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium Falciparum Subclinical Parasitemia in HIV-infected Adults With CD4+ Counts >200 and <500 Cells/mm^3
Verified date | July 2019 |
Source | AIDS Clinical Trials Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study was to see if antiretroviral therapy (ART) is safe and works at getting rid of malaria in blood and to see whether one type of ART is better than another. This study may offer information for further research in looking at whether ART plays a role in the prevention and treatment of malaria.
Status | Completed |
Enrollment | 52 |
Est. completion date | June 19, 2016 |
Est. primary completion date | June 19, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - HIV-1 infection - CD4+ count > 200 and < 500 cells/mm^3 obtained within 30 days prior to study entry at a DAIDS-approved laboratory. - Pf SCP confirmed in a laboratory approved to conduct parasitemia microscopy. Note: Pf SCP defined as meeting all three of the following criteria within 72 hours prior to study entry: 1. Microscopy confirmed parasitemia (see section 6.3.6 and the A5297 Manual of Procedures [MOPS]) 2. An oral temperature < 37.5°C. 3. The absence of Grade 2 or greater signs or symptoms thought to be related to clinical malaria including: 1. headache 2. malaise or fatigue 3. abdominal discomfort 4. muscle or joint pain 5. fever 6. chills 7. perspiration 8. anorexia 9. vomiting 10. other signs or symptoms thought to be related to clinical malaria - Certain laboratory values obtained within 14 days prior to study entry, as detailed in section 4.1.4 of the protocol. - Hepatitis B surface antigen (HBsAg) negative within 30 days prior to entry. - Female study volunteers of reproductive potential have a negative serum or urine pregnancy test performed within 72 hours prior to entry. - All study volunteers agree not to participate in a conception process (eg, active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization) for study duration. If participating in sexual activity that could lead to pregnancy, must agree to use two reliable forms of contraceptive simultaneously while receiving protocol-specified medications. One form of contraceptive must be a barrier method if a participant receives EFV. Participants must agree to continue the use of two contraceptives for 6 months after stopping EFV and 6 weeks after stopping all other protocol-specified medications. - Study volunteers who are not of reproductive potential are eligible without requiring the use of a contraceptive. - Ability and willingness of participant or legal guardian/representative to provide informed consent. - Willing and able to return to the clinic twice to three times a day for study visits. Exclusion Criteria: Step 1: Exclusion Criteria - Previous history or current use of ART. - Single dose NVP or dual therapies used for Prevention of mother-to-child transmission (PMTCT) within 2 years prior to entry. - Use of any medication with antimalarial activity, including TMP/SMX (see list of prohibited medications in the A5297 Manual of Procedures (MOPS)), within 14 days prior to study entry. - Confirmed or clinically suspected OIs (including but not limited to tuberculosis, clinical malaria, PCP), or other pulmonary or gastrointestinal infections for which potential participants did not complete treatment more than 30 days prior to enrollment or have signs and symptoms during screening. - Breastfeeding. - Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation. - Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. - Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to entry. - Results suggestive of active pulmonary disease from a chest x-ray performed within 30 days prior to study entry. |
Country | Name | City | State |
---|---|---|---|
Kenya | AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601) | Eldoret | |
Kenya | Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501) | Kericho | |
Kenya | Kisumu Crs (31460) | Kisumu | |
Malawi | College of Med. JHU CRS (30301) | Blantyre | |
Uganda | Joint Clinical Research Centre (JCRC) (12401) | Kampala |
Lead Sponsor | Collaborator |
---|---|
AIDS Clinical Trials Group | National Institute of Allergy and Infectious Diseases (NIAID) |
Kenya, Malawi, Uganda,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Participants With Plasmodium Falciparum (Pf) Subclinical Parasitemia (SCP) Clearance | Pf SCP clearance defined by polymerase chain reaction (PCR) < 10 parasites/µL on three consecutive occasions within a 24-hour period. If a participant had missing data on day 15, they were considered as not having clearance. |
Day 15 (3 samples collected, separated by at least 5 hours and all three collected within 24-hours) | |
Secondary | Time to First Pf SCP Clearance | Time to clearance is defined by time to first measurement with PCR < 10 parasites/µL, and is evaluated as the point estimate and 95% CI for the day when 50% of participants cleared parasite. | From study entry up to day 30 | |
Secondary | Log10(Pf Parasite Density) | Pf parasite density was determined by PCR. If parasite density equals 0, the value is set to 0.01 before log10 transformation. The value 0.01 was chosen based on the smallest observed parasite density value of 0.017. | Entry, days 3, 6, 9, 12, 15, 20, 25, 30 | |
Secondary | Change in log10(Pf Parasite Density) From Entry to Day 30 | Change is evaluated as log10(Pf parasite density) at day 30 minus log10(Pf parasite density) at entry. Change is evaluated in four groups: Randomized to nNRTI-based ART with continued Pf SCP at day 15 Randomized to nNRTI-based ART with clearance of Pf SCP at day 15 Randomized to LPV/r-based ART with continued Pf SCP at day 15 Randomized to LPV/r-based ART with clearance of Pf SCP at day 15 |
Entry, Day 30 | |
Secondary | Number of Participants With Uncomplicated Clinical Malaria | Uncomplicated clinical malaria is defined as the presence of non-severe fever/symptoms and parasitemia without organ complication. | From study entry to day 30 | |
Secondary | Number of Participants With Detectable Pf Gametocyte Density | Number of participants with detectable Pf gametocyte density as determined by PCR. Due to the large number of undetectable results, this outcome was measured as dichotomous. | Entry, days 3, 6, 9, 12, 15, 20, 25, 30 | |
Secondary | Change in log10(Pf Gametocyte Density) From Entry to Day 30 | Change in log10(Pf gametocyte density) as evaluated using a Hodges-Lehmann estimate from entry to day 30 is evaluated in two groups: Randomized to nNRTI-based ART with continued Pf SCP at day 15 Randomized to LPV/r-based ART with continued Pf SCP at day 15 Analysis was not conducted in either group with clearance at day 15 due to the small sample size and high number of undetectable samples in both clearance groups at entry and day 30. |
Entry, Day 30 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03188523 -
Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)
|
Phase 1 | |
Recruiting |
NCT06185452 -
Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine
|
Phase 4 | |
Recruiting |
NCT02881320 -
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1
|
Phase 2/Phase 3 | |
Completed |
NCT02513771 -
Sitagliptin for Reducing Inflammation and Immune Activation
|
Phase 2 | |
Completed |
NCT02542852 -
A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia
|
Phase 2 | |
Completed |
NCT02057796 -
Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3
|
Phase 4 | |
Terminated |
NCT02732457 -
Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients
|
||
Completed |
NCT01989910 -
Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients
|
Phase 4 | |
Completed |
NCT01704781 -
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)
|
Phase 1/Phase 2 | |
Completed |
NCT01627678 -
Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART
|
Phase 1/Phase 2 | |
Completed |
NCT01466595 -
Rifaximin as a Modulator of Microbial Translocation and Immune Activation
|
Phase 2 | |
Completed |
NCT01348308 -
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT01403051 -
High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART
|
Phase 2 | |
Completed |
NCT01019551 -
Therapeutic Intensification Plus Immunomodulation in HIV-infected Patients
|
Phase 2 | |
Completed |
NCT01511809 -
Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression
|
Phase 3 | |
Terminated |
NCT01130376 -
Novel Interventions in HIV-1 Infection
|
Phase 1 | |
Completed |
NCT00323687 -
SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada
|
Phase 4 | |
Completed |
NCT04003103 -
Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
|
Phase 2 | |
Completed |
NCT02527096 -
A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)
|
Phase 2 | |
Active, not recruiting |
NCT04776252 -
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
|
Phase 3 |